Evidence map›Paper›PMID 41255672›Full record

ArticleWorld journal of clinical pediatrics2025

Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children.

Elizaveta Makarova, Olga Goleva, Tatiana Gabrusskaya, Natalia Lubimova, Natalia Ulanova, Natalia Volkova, Elena Shilova, Maria Revnova, Susanna Kharit, Mikhail Kostik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizaveta MakarovaDepartment of Polyclinic Pediatrics, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg 194100, Russia.
Olga GolevaDepartment of Experimental Medical Virology, Molecular Genetics and Biobanking, Federal Research and Clinical Center for Infectious Diseases, Saint Petersburg 197022, Russia.
Tatiana GabrusskayaDepartment of Children's Diseases named after Professor I. M. Vorontsov, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia.
Natalia LubimovaDepartment of Pediatric 1, Almazov National Medical Research Centre, Saint Petersburg 197341, Russia.
Natalia UlanovaDepartment of Gastroenterology, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia.
Natalia VolkovaDepartment of Gastroenterology, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia.
Elena ShilovaDepartment of Gastroenterology, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia.
Maria RevnovaDepartment of Polyclinic Pediatrics, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg 194100, Russia.
Susanna KharitResearch Department of Vaccine Prevention and Post-Vaccination Pathology, Federal Research and Clinical Center for Infectious Diseases, Saint Petersburg 197022, Russia.
Mikhail KostikHospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint Petersburg 194100, Russia. kost-mikhail@yandex.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren with juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) face an elevated risk of severe infection owing to their diseases and the immunosuppressive treatment for disease control.

aimTo compare scheduled vaccination coverage and the levels of post-vaccine antibodies against measles, mumps, rubella (MMR) and hepatitis B in pediatric patients with IBD and JIA.

methodsA comparative cohort study included 97 patients with IBD and 170 patients with JIA. Vaccination history was obtained from medical records, while post-vaccination immunity was assessed prospectively by measuring specific IgG antibody titers using enzyme-linked immunosorbent assays (Vector-Best JSC, Russia; IBL International, Germany) during routine visits between January 2022 and April 2023.

resultsA complete two-dose MMR course had been administered to 66.3% of IBD patients and 55.9% of JIA patients (

conclusionPatients with IBD and JIA demonstrated different vaccination coverage patterns and levels of anti-vaccine antibodies. Routine baseline serology and timely booster vaccination should be implemented for all pediatric patients receiving chronic immunosuppression.

Indexed as

Anti-vaccine antibodiesHepatitis BInflammatory bowel diseaseJuvenile idiopathic arthritisMeaslesMumpsRubellaVaccines

Identifiers

PMID41255672
PMCPMC12620767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.